Inspire Medical Systems, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Inspire Medical Systems, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $26.91M | Feb 25, 2020 |
| FY2019 | Sep 30, 2019 | $20.86M | Feb 25, 2020 |
| FY2019 | Jun 30, 2019 | $18.03M | Feb 25, 2020 |
| FY2019 | Mar 31, 2019 | $16.25M | Feb 25, 2020 |
| FY2019 | Dec 31, 2018 | $16.56M | Feb 25, 2020 |
| FY2019 | Sep 30, 2018 | $13.05M | Feb 25, 2020 |
| FY2019 | Jun 30, 2018 | $10.94M | Feb 25, 2020 |
| FY2019 | Mar 31, 2018 | $10.04M | Feb 25, 2020 |
| FY2019 | Dec 31, 2017 | $28.57M | Feb 25, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $911.98M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $802.80M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $624.80M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $407.86M | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | $233.39M | Feb 9, 2024 |
| FY2020 | Dec 31, 2020 | $46.01M | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | $35.84M | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | $12.18M | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | $21.35M | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | $26.91M | Feb 24, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $778.76M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $679.82M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $528.22M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $341.74M | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | $200.12M | Feb 9, 2024 |
| FY2020 | Dec 31, 2020 | $38.85M | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | $30.63M | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | $10.23M | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | $18.05M | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | $22.67M | Feb 24, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $145.42M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $53.51M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | ($21.15M) | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | ($44.88M) | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | ($42.04M) | Feb 9, 2024 |
| FY2020 | Dec 31, 2020 | ($7.48M) | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | ($10.39M) | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | ($23.09M) | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | ($16.25M) | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | ($9.08M) | Feb 24, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $50.95M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $36.08M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | ($40.27M) | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | ($47.59M) | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | ($39.85M) | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | ($56.21M) | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | ($34.90M) | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | ($20.38M) | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | ($16.00M) | Feb 25, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $103.17M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $114.13M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $116.54M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $68.65M | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | $37.35M | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $26.09M | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $12.84M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $7.39M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $6.19M | Feb 25, 2020 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $624.64M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $529.61M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $451.96M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $320.69M | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | $202.62M | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $127.87M | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $90.47M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $53.53M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $32.36M | Feb 25, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $116.98M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $130.25M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $24.65M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $11.57M | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | ($20.12M) | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | ($53.05M) | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | ($32.85M) | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | ($18.69M) | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | ($15.79M) | Feb 25, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.50M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $39.12M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $23.63M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $9.10M | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | $4.67M | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $2.46M | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $2.74M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $250.0K | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $412.0K | Feb 25, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $907.32M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $808.38M | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $676.81M | Feb 10, 2025 |
| FY2023 | Dec 31, 2022 | $564.88M | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | $295.08M | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $281.19M | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $181.25M | Feb 24, 2021 |
| FY2019 | Jan 1, 2019 | $200.09M | Feb 25, 2020 |
| FY2019 | Dec 31, 2018 | $200.08M | Feb 25, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $126.16M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $118.69M | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $104.30M | Feb 10, 2025 |
| FY2023 | Dec 31, 2022 | $68.87M | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | $66.04M | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $51.44M | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $41.42M | Feb 24, 2021 |
| FY2019 | Jan 1, 2019 | $36.10M | Feb 25, 2020 |
| FY2019 | Dec 31, 2018 | $36.08M | Feb 25, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $781.16M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $689.70M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $572.51M | Feb 13, 2026 |
| FY2025 | Dec 31, 2022 | $496.01M | Feb 13, 2026 |
| FY2024 | Dec 31, 2021 | $229.05M | Feb 10, 2025 |
| FY2023 | Dec 31, 2020 | $229.75M | Feb 9, 2024 |
| FY2022 | Dec 31, 2019 | $139.84M | Feb 10, 2023 |
| FY2021 | Dec 31, 2018 | $164.00M | Feb 15, 2022 |
| FY2020 | Dec 31, 2017 | $1.33M | Feb 24, 2021 |
| FY2019 | Dec 31, 2016 | ($6.61M) | Feb 25, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($146.49M) | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | ($291.91M) | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | ($345.42M) | Feb 10, 2025 |
| FY2023 | Dec 31, 2022 | ($324.27M) | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | ($279.39M) | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | ($237.35M) | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | ($180.16M) | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | ($146.91M) | Feb 25, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $104.81M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $150.15M | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $185.54M | Feb 10, 2025 |
| FY2023 | Dec 31, 2022 | $441.59M | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | $214.47M | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $190.52M | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $22.86M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $97.29M | Feb 25, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $24.50M | Feb 15, 2022 |
| FY2020 | Dec 31, 2020 | $24.50M | Feb 24, 2021 |
| FY2019 | Dec 31, 2019 | $24.50M | Feb 25, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4 | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Feb 15, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4 | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 10, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Feb 15, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 28.58M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 29.74M | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | 29.56M | Feb 10, 2025 |
| FY2023 | Dec 31, 2022 | 29.01M | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | 27.42M | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | 27.07M | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | 24.11M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | 23.40M | Feb 25, 2020 |